3 recruiting, 2 completed, 2 terminated, 2 withdrawn. 6 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Recruiting 3, Withdrawn 2, Terminated 1 |
| Phase 2 | 5 | Completed 2, Terminated 2, Withdrawn 1 |
Follow Context Therapeutics Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 1a/1b, First-Time-in-Human Study of CT-202, a Nectin-4 Directed Bispecific Antibody, in Participants With Recurring Triple Negative Breast, Colorectal, Urothelial Cancers CT-202 - Triple Negative Breast Cancer (TNBC), Colorectal Cancer | Phase 1 | Recruiting | Context Therapeutics Inc. | 162 | 2026-09-01 | 2026-10-08 |
| CT-95 in Advanced Cancers Associated With Mesothelin Expression CT-95 - Mesothelin-Expressing Tumors, Epithelial Ovarian Cancer | Phase 1 | Recruiting | Context Therapeutics Inc. | 70 | 2025-03-31 | 2026-06-12 |
| A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors CTIM-76 - Platinum-resistant Ovarian Cancer, Testicular Cancer | Phase 1 | Recruiting | Context Therapeutics Inc. | 156 | 2024-07-10 | 2026-09-03 |
| A Rollover Protocol of Elacestrant, in Combination With Onapristone, for Patients With ER+, PR+, HER2- Advanced or Metastatic Breast Cancer Elacestrant, Onapristone - Breast Cancer | Phase 1 / Phase 2 | Withdrawn | Context Therapeutics Inc. | 2023-06-01 | 2025-04-22 | |
| Study of Elacestrant in Combination With Onapristone in Patients With Advanced or Metastatic Breast Cancer Elacestrant, Onapristone - Breast Cancer | Phase 1 / Phase 2 | Terminated | Context Therapeutics Inc. | 4 | 2022-12-02 | 2026-07-21 |
| Onapristone and Fulvestrant for ER+ HER2- Metastatic Breast Cancer After Endocrine Therapy and CDK4/6 Inhibitors (The SMILE Study) Onapristone, Fulvestrant - ER-positive Breast Cancer, HER2-negative Breast Cancer | Phase 2 | Terminated | University of Wisconsin, Madison | 11 | 2021-10-05 | 2024-05-03 |
| A Study of Letrozole, Palbociclib, and Onapristone ER in People With Metastatic Breast Cancer Letrozole, Palbociclib, Onapristone ER - Metastatic Breast Cancer, Unresectable Breast Cancer | Phase 1 | Withdrawn | Memorial Sloan Kettering Cancer Center | 2021-09-09 | 2023-04-28 | |
| Onapristone and Anastrozole for the Treatment of Refractory Hormone Receptor Positive Endometrial Cancer Extended-release Onapristone, Anastrozole, Quality-of-Life Assessment - Refractory Endometrial Adenocarcinoma, Refractory Endometrial Carcinoma | Phase 2 | Completed | Thomas Jefferson University | 14 | 2021-01-28 | 2026-07-17 |
| A Study of Onapristone ER Alone Or In Combination With Anastrozole in Gynecologic Cancers That Respond to Progesterone Onapristone ER, Onapristone ER + Anastrozole - Granulosa Cell Ovarian Cancer, Low Grade Serous Ovarian/ Primary Peritoneal Cancer | Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 34 | 2019-05-02 | 2025-07-28 |
Breast Neoplasms (3) · Colorectal Neoplasms (2) · Endometrial Neoplasms (2) · Neoplasm Metastasis (2) · Carcinoma, Ovarian Epithelial (1) · Mesothelioma, Malignant (1) · Neoplasms (1) · Testicular Neoplasms (1) · Triple Negative Breast Neoplasms (1)
onapristone (3) · Anastrozole (2) · RAD1901 (2) · elacestrant (2) · Fulvestrant (1) · Letrozole (1) · palbociclib (1)
United States (8) · Australia (1) · United Kingdom (1)
Karen Chagin, MD (2) · Kari B Wisinski, MD (1) · Komal Jhaveri, MD (1) · Rachel Grisham, MD (1) · Sailaja Kamaraju, MD, MS (1) · Tommy Buchanan, MD (1)